Search results
Showing 31 to 45 of 544 results for iv
prescribing and delivering IV fluids for children and young people are appropriately trained in the principles of fluid prescribing and...
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Hampshire Hospitals NHS Foundation Trust Adult Fluid Prescription Chart 2014
the prescription of intravenous fluids for adult inpatients. It contains information about the different constituents of...
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Glucose concentration:- What is the most appropriate glucose concentration in IV fluids for children and young people of different ages?...
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
is the effectiveness of localised treatment for people with stages III and IV melanoma? Any explanatory notes(if applicable) For a short...
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Recommendation ID NG72/1 Question Predictive accuracy of the WPPSI-IV at age 4 years (uncorrected) for children born preterm:- What is...